HRP20030932A2 - Cytotoxic cd44 antibody immunoconjugates - Google Patents

Cytotoxic cd44 antibody immunoconjugates

Info

Publication number
HRP20030932A2
HRP20030932A2 HR20030932A HRP20030932A HRP20030932A2 HR P20030932 A2 HRP20030932 A2 HR P20030932A2 HR 20030932 A HR20030932 A HR 20030932A HR P20030932 A HRP20030932 A HR P20030932A HR P20030932 A2 HRP20030932 A2 HR P20030932A2
Authority
HR
Croatia
Prior art keywords
cytotoxic
antibody immunoconjugates
immunoconjugates
antibody
Prior art date
Application number
HR20030932A
Other languages
English (en)
Inventor
Guenther Adolf
Karl-Heinz Heider
Erik Patzelt
Marlies Sproll
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of HRP20030932A2 publication Critical patent/HRP20030932A2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
HR20030932A 2001-05-18 2003-11-14 Cytotoxic cd44 antibody immunoconjugates HRP20030932A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01112227A EP1258255A1 (en) 2001-05-18 2001-05-18 Conjugates of an antibody to CD44 and a maytansinoid
PCT/EP2002/005413 WO2002094325A2 (en) 2001-05-18 2002-05-16 Cytotoxic cd44 antibody immunoconjugates

Publications (1)

Publication Number Publication Date
HRP20030932A2 true HRP20030932A2 (en) 2004-04-30

Family

ID=8177473

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030932A HRP20030932A2 (en) 2001-05-18 2003-11-14 Cytotoxic cd44 antibody immunoconjugates

Country Status (24)

Country Link
EP (2) EP1258255A1 (xx)
JP (1) JP2004529963A (xx)
KR (1) KR20030097883A (xx)
CN (1) CN1509187A (xx)
AR (1) AR035977A1 (xx)
BG (1) BG108366A (xx)
BR (1) BR0209862A (xx)
CA (1) CA2443438A1 (xx)
CO (1) CO5550468A2 (xx)
CZ (1) CZ20033477A3 (xx)
EA (1) EA200301159A1 (xx)
EE (1) EE200300568A (xx)
HR (1) HRP20030932A2 (xx)
HU (1) HUP0400046A3 (xx)
IL (1) IL157965A0 (xx)
MX (1) MXPA03010432A (xx)
NO (1) NO20035108D0 (xx)
NZ (1) NZ530167A (xx)
PE (1) PE20021097A1 (xx)
PL (1) PL365480A1 (xx)
SK (1) SK15582003A3 (xx)
WO (1) WO2002094325A2 (xx)
YU (1) YU91503A (xx)
ZA (1) ZA200307364B (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
DE10256083A1 (de) * 2002-11-29 2004-08-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
DK1651162T3 (en) * 2003-05-20 2016-02-01 Immunogen Inc IMPROVED CYTOTOXIC AGENTS WITH NEW MAYTANSINOIDS
DE602004031239D1 (de) * 2003-07-21 2011-03-10 Immunogen Inc Verfahren zu dessen anwendung
EP1716179A2 (en) * 2004-02-12 2006-11-02 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
NZ555601A (en) * 2004-12-09 2009-07-31 Centocor Inc Anti-integrin immunoconjugates, methods and uses
US20060182750A1 (en) * 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing stable drug conjugates
EP1861425B1 (en) 2005-03-10 2012-05-16 Morphotek, Inc. Anti-mesothelin antibodies
CN101374545B (zh) * 2005-04-15 2012-03-28 免疫基因公司 消除肿瘤中的异质或混合细胞群体
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
EP1928503B1 (en) 2005-08-24 2012-10-03 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
EP1806365A1 (en) * 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
AR059900A1 (es) * 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
PL2437790T3 (pl) 2009-06-03 2019-09-30 Immunogen, Inc. Sposoby sprzęgania
TW201117814A (en) * 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
KR20220123130A (ko) 2011-03-29 2022-09-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
GB201220889D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating metastasizing cancers
GB201220891D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating breast cancers
GB201220901D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating pancreatic cancer
GB201220899D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived pegylated peptides
KR102252925B1 (ko) 2013-08-26 2021-05-18 리제너론 파마슈티칼스 인코포레이티드 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
WO2016150521A1 (en) * 2015-03-26 2016-09-29 Fundación Imdea Nanociencia Functionalised magnetic nanoparticle
JP7540683B2 (ja) 2016-06-06 2024-08-27 ノースウェスタン ユニバーシティ 融合タンパク質コンストラクト
EP3755717A4 (en) * 2018-02-22 2022-01-26 Multitude Inc. THERAPEUTIC ANTIBODIES AND ASSOCIATED USES
CN114057874B (zh) * 2020-07-31 2023-05-05 北京市神经外科研究所 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
DE19648209A1 (de) * 1996-11-21 1998-05-28 Boehringer Ingelheim Int Verfahren zur Tumorzelldepletion CD34-positiver Zellen
DE19708713C2 (de) * 1997-03-04 2002-11-28 Boehringer Ingelheim Int Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
ES2466715T3 (es) * 1999-06-25 2014-06-11 Immunogen, Inc. Métodos de tratamiento usando conjugados de anticuerpo anti-ErbB-maitansinoide
CA2385528C (en) * 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents

Also Published As

Publication number Publication date
WO2002094325A3 (en) 2003-04-17
PL365480A1 (en) 2005-01-10
KR20030097883A (ko) 2003-12-31
NZ530167A (en) 2005-10-28
CA2443438A1 (en) 2002-11-28
JP2004529963A (ja) 2004-09-30
NO20035108L (no) 2003-11-17
BR0209862A (pt) 2004-06-08
MXPA03010432A (es) 2004-04-02
HUP0400046A3 (en) 2006-02-28
EP1258255A1 (en) 2002-11-20
HUP0400046A2 (hu) 2004-04-28
YU91503A (sh) 2006-05-25
AR035977A1 (es) 2004-07-28
WO2002094325A2 (en) 2002-11-28
EA200301159A1 (ru) 2004-06-24
SK15582003A3 (sk) 2004-04-06
EE200300568A (et) 2004-04-15
PE20021097A1 (es) 2003-02-13
EP1395290A2 (en) 2004-03-10
CZ20033477A3 (en) 2004-05-12
BG108366A (bg) 2004-09-30
NO20035108D0 (no) 2003-11-17
IL157965A0 (en) 2004-03-28
CN1509187A (zh) 2004-06-30
ZA200307364B (en) 2004-04-20
CO5550468A2 (es) 2005-08-31

Similar Documents

Publication Publication Date Title
IL157965A0 (en) Cytotoxic cd44 antibody immunoconjugates
HUS1700038I1 (hu) Calicheamicin származék-hordozó konjugátumok
HUP0400466A3 (en) G-csf conjugates
EP1432444A4 (en) ANTI-BETA ANTIBODIES
HK1074206A1 (en) Anti-trail-r antibodies
ZA200400521B (en) Antibodies to OPGL.
MXPA03009390A (es) Anticuerpos para integrina vla-1.
EP1383801A4 (en) ANTIBODIES AGAINST CANCER
GB0009887D0 (en) Cytotoxic agents
AU2002365649A8 (en) Anti-dota antibody
GB0126378D0 (en) Antigen
HK1065063A1 (en) Oligonucleotide conjugates
EP1392204A4 (en) BIFUNCTIONAL ENERGY REVERSIBLE ACYL COMPOSITIONS
ZA200110500B (en) Pharmaceutical composition.
MXPA03007318A (es) Composicion farmaceutica.
ZA200110501B (en) Pharmaceutical composition.
ZA200110499B (en) Pharmaceutical composition.
GB0122196D0 (en) Improvements to the n-plex transceiver
AU7426601A (en) Gene-regulating conjugates
GB0119004D0 (en) Antibody
ZA200204623B (en) G-CSF conjugates.
GB0126680D0 (en) Pharmacopoeia
GB0119479D0 (en) Antigens
GB0111492D0 (en) Antigens
GB0112448D0 (en) Antigens

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn